KROSKeros Therapeutics, Inc.
Keros Therapeutics, Inc. (KROS) develops novel therapeutics for disorders linked to dysfunction in the endocannabinoid system. The next catalyst is Oct 6, 2026 — Initiation of KER-065 (DMD), which will test the company’s ability to advance its lead asset into Phase 3.
- Revenue surged 6,775% YoY to $32.8M, but net income remains -$83.41M, with a TTM net margin of -254.3%.
- Shareholders’ equity stands at $303.13M, with diluted EPS of -1.45.
- The company is heavily leveraged, with a capital structure that includes significant debt and equity financing.
The Read
KROS stock has historically shown high volatility before key catalysts, with a 45.
The schedule
No upcoming catalysts on the current packet.
Past
- Tue6Oct
Actual outcome: Mixed · $11.25 at outcome
Keros Therapeutics initiated its clinical trial for KER-065 in Duchenne muscular dystrophy (DMD), advancing its pipeline as anticipated. The stock experienced a muted 1.9% move, reflecting that while the trial initiation is a positive operational step, investors are likely waiting for tangible clinical data to validate efficacy and safety before driving the shares toward the modeled bull or bear targets.
The initiation of KER-065 (DMD) will test the company's ability to advance its pipeline and attract investor confidence.
- Mon3Aug
Actual outcome: Bull · $11.20 at outcome
Despite Q2 revenues falling to zero, Keros met EPS estimates of -$0.64 and the stock rallied 10.3%. The upward move was driven by the company's extended cash runway into the first half of 2028 and focus on upcoming rinvatercept pipeline milestones, which overshadowed the lack of current revenue. Additionally, a recent development milestone payment from partner Takeda helped bolster confidence in the company's financial stability and long-term growth prospects.
Quarterly earnings update with a focus on cash preservation and operational burn rate.
- Mon8Jun
Actual outcome: Bear · $10.23 at outcome
Keros Therapeutics reported an in-line EPS of -$0.64 and management participated in a fireside chat at the Goldman Sachs Global Healthcare Conference. Although shares edged up slightly following the update, the absence of major new clinical data ahead of ASH failed to drive a meaningful recovery, leaving the stock to close at $10.24 and firmly below the $11.50 bear floor.
Q3 2026 earnings will mainly serve to refresh Keros’ cash runway and provide a status update on KER-050 ahead of full ASH data; steady operating trends and reassurance on liquidity could nudge shares toward $14.50, while higher-than-expected burn or vague commentary ahead of ASH could drag the stock toward $14.50.
- Thu14May
Actual outcome: Bull · $12.07 at outcome
Price reached or exceeded bull target ($13.20) at outcome date.
Q1 2026 earnings will update the market on Keros’ post-partnership revenue step-down, R&D spend around KER-050 Phase 3, and the cash runway after ending 2025 with $287.4M in cash; confirmation of disciplined burn and a runway beyond key KER-050 data could support a move toward $13.20, while another noisy quarter with wider losses or a shorter-than-expected runway could push shares toward $13.20.
